Skip to content

Ultrasound Guided Celiac Plexus Neurolysis

Comparison Between Two Volumes Of 70% Alcohol In Single Injection Ultrasound Guided Celiac Plexus Neurolysis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201803003212106
Enrollment
32
Registered
2018-03-18
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer cancer

Interventions

Group I (CPN 20)
Group II (CPN 40)

Sponsors

suez canal university hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Adult patients of either sex 18 years or older. 2.Patients with the diagnosis of histologically proven or radiologically consistent, surgically unresectable upper abdominal malignancies (including gastric, pancreatic, biliary system). 3.Patients with visual analogue scale (VAS) scores of equal to or more than 4/10 due to cancer related visceral pain in spite of adequate medical management (defined as the highest analgesia possible without intolerable side effects using opioid and non-opioid drugs according to the world health organization analgesic step ladder).

Exclusion criteria

Exclusion criteria: 1.Refusal of participation in the study. 2.Patients received celiac or splanchnic blocks previously as a neurolytic management for cancer pain or those who did not respond to the diagnostic anesthetic block. 3.Patients received intrathecal or epidural interventional implantable devices for cancer pain. 4.Patients allergic to local anesthetics used in the diagnostic block. 5.Patients with coagulopathies not correctable with active medical management. 6.Patients with uncontrolled hypotension. 7.Patients suffering from pain not related to the abdominal malignancy such as neuropathic pain or central pain conditions. 8.Patients with documented metastatic lesions in other sites of the body contributing to pain severity. 9.Patients with psychiatric disorders preventing adequate assessment and data collection.

Design outcomes

Primary

MeasureTime frame
visual analogue scale scores

Secondary

MeasureTime frame
total daily opioid consumption ;quality of life using the general functional assessment of cancer therapy scale (FACT-G);heamodynamics:heart rate , systolic blood pressure , diastolic blood pressure , mean arterial pressures and pulse oximetry saturation ;Complications of the procedure including hypotension, diarrhea, hematoma, infection, procedure related pain, neurologic complications, and mortality

Countries

Egypt

Contacts

Public ContactReda Ismail

lecturer of anesthesia and intensive care

dr.rowda@yahoo.com002-01224997298

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026